Trulieve Cannabis (NYSE:TRLV) Given Overweight Rating at Cantor Fitzgerald

Trulieve Cannabis (NYSE:TRLV)‘s stock had its “overweight” rating restated by Cantor Fitzgerald in a research note issued on Friday, Benzinga reports. They currently have a $15.00 target price on the stock. Cantor Fitzgerald‘s target price would suggest a potential upside of 40.78% from the company’s previous close.

A number of other equities analysts have also recently issued reports on the stock. Wall Street Zen cut shares of Trulieve Cannabis from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Trulieve Cannabis in a report on Friday, September 11th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $15.00.

Trulieve Cannabis Trading Down 1.5%

NYSE TRLV traded down $0.17 during trading on Friday, hitting $10.66. The company had a trading volume of 867,261 shares, compared to its average volume of 962,328. The stock has a fifty day simple moving average of $11.17. The company has a current ratio of 5.94, a quick ratio of 3.98 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $2.05 billion and a P/E ratio of 96.86. Trulieve Cannabis has a one year low of $4.62 and a one year high of $13.28.

Trulieve Cannabis (NYSE:TRLV) last posted its earnings results on Friday, August 7th. The company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.05. The firm had revenue of $271.00 million for the quarter, compared to the consensus estimate of $268.82 million. Trulieve Cannabis had a negative return on equity of 4.24% and a negative net margin of 41.55%. As a group, equities analysts anticipate that Trulieve Cannabis will post 0.31 EPS for the current year.

Hedge Funds Weigh In On Trulieve Cannabis

Several institutional investors have recently added to or reduced their stakes in TRLV. Marion Wealth Management bought a new position in shares of Trulieve Cannabis during the 3rd quarter valued at approximately $109,000. PFS Partners LLC bought a new position in Trulieve Cannabis in the third quarter worth approximately $33,000. Finally, Prime Capital Investment Advisors LLC bought a new stake in shares of Trulieve Cannabis in the third quarter valued at about $770,000.

About Trulieve Cannabis

Trulieve Cannabis Corp. is a vertically integrated cannabis company that cultivates, processes and sells medical and adult-use cannabis products. Its offerings include flower, pre-rolls, concentrates, vaporizers, edibles, tinctures, capsules and topical products, sold through retail dispensaries and other approved channels under brands such as Trulieve, Cultivar Collection, Muse, Roll One and Alchemy.

Founded in 2015, Trulieve initially built its business around Florida’s medical cannabis market and later expanded into additional U.S.